Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a "Pipeline in a Product" -February 21, 2024 at 08:16 am EST
Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways in neurodegenerative diseases Expansion of COYA 302 into...
United States Howard Berman Jason Thonhoff David Beers Stanley Appel Additional Clinical Development Updates
Source: marketscreener.com